Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sol-Gel TechnologiesSLGL +2.89%55 Equity-to-Asset is 0.88 as of Mar. 2026, which is 2% above its 10-year median of 0.86. GuruFocus rates SLGL with a GF Score™ of 55/100 and a GF Value™ of $66.33 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 1,417 Biotechnology companies, Sol-Gel Technologies ranks better than 79.25% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Sol-Gel Technologies's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $51.41 Mil. Sol-Gel Technologies's Total Assets for the quarter that ended in Mar. 2026 was $58.55 Mil.
Therefore, Sol-Gel Technologies's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.88.
The historical rank and industry rank for Sol-Gel Technologies's Equity-to-Asset or its related term are showing as below:
SLGL'
s Equity-to-Asset Range Over the Past 10 Years
Min: -3.44 Med: 0.86 Max: 0.97
Current: 0.88
During the past 11 years, the highest Equity to Asset Ratio of Sol-Gel Technologies was 0.97. The lowest was -3.44. And the median was 0.86.
SLGL's Equity-to-Asset is ranked better than 79.25% of 1417
companies
in the Biotechnology industry
Industry Median: 0.68
vs SLGL: 0.88
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Sol-Gel Technologies Equity-to-Asset Related Terms
Sol-Gel Technologies Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Sol-Gel Technologies's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SLGL vs AVXL, FATE, FHTX: Equity-to-Asset Comparison
For the Biotechnology subindustry, Sol-Gel Technologies's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sol-Gel Technologies Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sol-Gel Technologies's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Sol-Gel Technologies's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Sol-Gel Technologies's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sol-Gel Technologies (SLGL) has a Equity-to-Asset of 0.88 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Sol-Gel Technologies and its competitors. This is near median its historical median of 0.86. According to the industry distribution chart, Sol-Gel Technologies ranks #294 out of 1417 companies in the Biotechnology industry, placing it in the top 20.7%.
Is Sol-Gel Technologies' Equity-to-Asset too high?
Sol-Gel Technologies' current Equity-to-Asset of 0.88 is near median its 10-year median of 0.86. The Biotechnology industry median Equity-to-Asset is 0.68. Sol-Gel Technologies' value of 0.88 is 29.4% above this industry median. Based on the distribution chart, Sol-Gel Technologies ranks #294 out of 1417 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sol-Gel Technologies has a GF Score™ of 55/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sol-Gel Technologies' Equity-to-Asset compare to AVXL and FATE?
According to the Biotechnology industry distribution chart, Sol-Gel Technologies ranks #294 out of 1417 companies for Equity-to-Asset. This places Sol-Gel Technologies in the top 21% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.68. Sol-Gel Technologies' value of 0.88 is 29.4% above this benchmark. While the company's 10-year median is 0.86 vs. the industry median of 0.68, Sol-Gel Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sol-Gel Technologies's current Equity-to-Asset of 0.88 is 29.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Sol-Gel Technologies and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sol-Gel Technologies's current Equity-to-Asset is 0.88, which is near median its own 10-year median of 0.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sol-Gel Technologies stock overvalued right now?
Based on GuruFocus' analysis, Sol-Gel Technologies (SLGL) is currently considered Modestly Overvalued. The stock's GF Value™ is $66.33, compared to a current price of $81.96 — trading 23.6% above its estimated fair value. The current Equity-to-Asset is 0.88, which is near median its 10-year median of 0.86 and 29.4% above the Biotechnology industry median of 0.68. Sol-Gel Technologies' overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Sol-Gel Technologies (SLGL), the current Equity-to-Asset is 0.88 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sol-Gel Technologies (SLGL) Overvalued in 2026?
Based on GuruFocus' analysis, Sol-Gel Technologies stock appears to be overvalued.
The current stock price of $81.96 is trading 23.6% above its estimated GF Value™ of $66.33.
GuruFocus considers Sol-Gel Technologies to be Modestly Overvalued.
Key valuation signals for SLGL:
Equity-to-Asset: 0.88 (near median its 10-year median of 0.86)
GF Value™: $66.33 vs. price of $81.96 (23.6% above fair value)
Industry Position: 29.4% above the Biotechnology median (#294 of 1417)
No single metric tells the full story. See the SLGL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
55GF Score
Get the complete analysis for SLGL
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLGL has been successfully added to your 
